| |
| |
|
| Insider
Information: |
Labrosse Nicole |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
15,480 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$597,064 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
15,480 |
|
|
| Total
Value |
$597,064 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Halozyme Therapeutics Inc |
HALO |
|
2024-02-16 |
15,480 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
24 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-02-16 |
4 |
D |
$36.10 |
$202,196 |
D/D |
(5,601) |
15,480 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,422 |
18,344 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-02-15 |
4 |
D |
$35.91 |
$24,634 |
D/D |
(686) |
10,659 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,254 |
11,345 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-02-10 |
4 |
D |
$35.49 |
$52,419 |
D/D |
(1,477) |
10,091 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,502 |
11,568 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,094 |
11,591 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-16 |
4 |
S |
$49.26 |
$124,382 |
D/D |
(2,525) |
9,066 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-15 |
4 |
D |
$49.20 |
$30,553 |
D/D |
(621) |
6,497 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,254 |
7,118 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-12 |
4 |
D |
$48.92 |
$33,315 |
D/D |
(681) |
5,864 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,389 |
6,545 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-10 |
4 |
D |
$48.92 |
$68,097 |
D/D |
(1,392) |
5,156 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2023-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,503 |
6,548 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2022-11-15 |
4 |
S |
$53.69 |
$269,053 |
D/D |
(5,000) |
4,045 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-15 |
4 |
D |
$34.43 |
$14,908 |
D/D |
(433) |
9,045 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,255 |
9,478 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,256 |
8,650 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-14 |
4 |
D |
$33.64 |
$14,364 |
D/D |
(427) |
8,223 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-12 |
4 |
D |
$34.20 |
$17,305 |
D/D |
(506) |
7,394 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,389 |
7,900 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-10 |
4 |
D |
$34.94 |
$35,814 |
D/D |
(1,025) |
6,511 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial Officer |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,503 |
7,536 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Financial OfficerOf |
• – – |
2022-02-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,033 |
|
% |
|
24 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
